Instil Bio, Inc. (TIL)

NASDAQ: TIL · Real-Time Price · USD
30.35
+3.60 (13.46%)
At close: May 29, 2025, 4:00 PM
30.66
+0.31 (1.02%)
After-hours: May 29, 2025, 5:44 PM EDT
13.46%
Market Cap 199.06M
Revenue (ttm) n/a
Net Income (ttm) -78.03M
Shares Out 6.56M
EPS (ttm) -11.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 646,394
Open 29.87
Previous Close 26.75
Day's Range 29.26 - 35.28
52-Week Range 9.62 - 92.00
Beta 1.80
Analysts Buy
Price Target 119.00 (+292.09%)
Earnings Date May 13, 2025

About TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol TIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $119.0, which is an increase of 292.09% from the latest price.

Price Target
$119.0
(292.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

Key catalyst: Phase 2 data from China in first-line NSCLC expected in 2H 2025, with enrollment completion projected for Q3 2025. The global non-small cell lung cancer therapeutics market size is proje...

4 days ago - Seeking Alpha

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced tha...

6 days ago - GlobeNewsWire

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions

7 days ago - GlobeNewsWire

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical ...

16 days ago - GlobeNewsWire

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025

3 months ago - GlobeNewsWire

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China

4 months ago - GlobeNewsWire

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.

5 months ago - Benzinga

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharm...

6 months ago - Seeking Alpha

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.

9 months ago - Benzinga

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global ...

9 months ago - GlobeNewsWire

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive...

9 months ago - Seeking Alpha

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its ...

10 months ago - GlobeNewsWire

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a ...

10 months ago - GlobeNewsWire

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its f...

1 year ago - GlobeNewsWire

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its...

1 year ago - GlobeNewsWire

Instil Bio Announces Strategic Update

DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...

1 year ago - GlobeNewsWire

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...

1 year ago - GlobeNewsWire

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...

1 year ago - GlobeNewsWire

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing...

1 year ago - GlobeNewsWire

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational i...

1 year ago - GlobeNewsWire

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors

2 years ago - GlobeNewsWire

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 ...

2 years ago - GlobeNewsWire

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil confirms cash runway beyond 2026

2 years ago - GlobeNewsWire

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Company anticipates cash resources to provide runway beyond 2026

2 years ago - GlobeNewsWire

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Other symbols: BCABIMRXNKTX
2 years ago - Barrons